Sanofi-a Ventis Deutschland Gmbh

Ascendis Pharma Endocrinology Division A/s

Ascendis Pharma Growth Disorders Division A/s

Ascendis Pharma A/s

Kennett Sprogoe

Harald Rau

Ulrich Hersel

Thomas Wegge

Oliver Keil

Susanne Kindermann

Grethe Norskov Rasmussen

Guillaume Maitro

Joachim Zettler

Nicola Bisek

Thomas Knappe

Samuel Weisbrod

Torben Lebmann

Burkhardt Laufer

Tobias Voigt

Felix Cleemann

Dirk Vetter

Torben Lessmann

Silvia Kaden-Vagt

Romy Reimann

Nora Kaluza

Susanne Kinderman

Sebastian Stark

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.

PEGylated Recombinant Human Growth Hormone Compounds

PEGylated recombinant human growth hormone compounds

The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.

Long acting insulin composition

Growing community of inventors

Palo Alto, CA, United States of America

Kennett Sprogoe